Abstract
Background: The impact of the new chemotherapy, fluorouracil plus leucovorin, oxali-platin, and docetaxel (FLOT) on body composition in gastric cancer (GC) patients remains un-known. We assessed body composition changes of GC patients receiving the FLOT regimen and their impact on treatment outcomes. Methods: Preoperative pre-and post-FLOT computed tomog-raphy (CT) scans of advanced GC patients were studied. Lumbar skeletal muscle index (SMI) and adipose indices were calculated before and after FLOT. Results: A total of 26 patients were identified between April 2019 and January 2020. Nineteen patients were sarcopenic at diagnosis. The mean BMI decreased (from 24.4 ± 3.7 to 22.6 ± 3.1; p < 0.0001) as well as the SMI (from 48.74 ± 9.76 to 46.52 ± 9.98; p = 0.009) and visceral adipose index (VAI) (from 49.04 ± 31.06 to 41.99 ± 23.91; p = 0.004) during preoperative FLOT therapy. BMI, SMI, and VAI variations were not associated with toxicity, Response Evaluation Criteria in Solid Tumors (RECIST), response, delay and completion of periop-erative FLOT chemotherapy, and the execution of gastrectomy; a decrease of SMI ≥ 5% was associated with a higher Mandard tumor regression grade (p = 0.01). Conclusions: Almost three-quarters (73.1%) of GC patients were sarcopenic at diagnosis. Preoperative FLOT was associated with a further reduction in SMI, BMI, and VAI. These changes were not associated with short-term outcomes.
Lingua originale | English |
---|---|
pagine (da-a) | 1-13 |
Numero di pagine | 13 |
Rivista | Nutrients |
Volume | 13 |
DOI | |
Stato di pubblicazione | Pubblicato - 2021 |
Keywords
- Adipose tissue
- Body composition
- FLOT
- Gastric cancer
- Muscle mass
- Neoad-juvant chemotherapy
- Personalized medicine
- SMI
- Sarcopenia
- Toxicity